

# Sumera Rizvi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10748437/publications.pdf>

Version: 2024-02-01

34  
papers

4,363  
citations

361296

20  
h-index

377752

34  
g-index

34  
all docs

34  
docs citations

34  
times ranked

5124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver Cancer Immunity. <i>Hepatology</i> , 2021, 73, 86-103.	3.6	52
2	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.3	1
3	The Two Faces of Relaxin in Cancer: Antitumor or Protumor?. <i>Hepatology</i> , 2020, 71, 1117-1119.	3.6	8
4	The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. <i>Molecular Cancer Research</i> , 2020, 18, 1574-1588.	1.5	16
5	Precarious Windows of Opportunity: Adverse Waitlist Dropout for Cholangiocarcinoma Versus Hepatocellular Carcinoma Patients. <i>Liver Transplantation</i> , 2020, 26, 1083-1084.	1.3	1
6	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
7	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019, 1, 297-311.	2.6	79
8	Animal models of cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 982-992.	1.8	50
9	Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. <i>Hepatology</i> , 2018, 68, 2428-2430.	3.6	1
10	Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2018, 68, 1228-1238.	1.8	17
11	Cholangiocarcinoma – evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
12	Targeting cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1454-1460.	1.8	62
13	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018, 38, 160-169.	1.8	50
14	YAP-associated chromosomal instability and cholangiocarcinoma in mice. <i>Oncotarget</i> , 2018, 9, 5892-5905.	0.8	45
15	A case of heart failure and diarrhoea. <i>Gut</i> , 2017, 66, 1778-1778.	6.1	2
16	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017, 66, 4-5.	6.1	5
17	Emerging molecular therapeutic targets for cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 632-644.	1.8	150
18	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 789-796.	0.6	26

#	ARTICLE	IF	CITATIONS
19	Liver capsule: Cholangiocarcinoma (CCA). <i>Hepatology</i> , 2016, 63, 1356-1356.	3.6	5
20	A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. <i>Journal of Biological Chemistry</i> , 2016, 291, 8031-8047.	1.6	74
21	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6 sensitive mechanism. <i>Hepatology</i> , 2015, 61, 1627-1642.	3.6	115
22	Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2152-2165.	2.4	100
23	Molecular Profiling and Research of Therapeutic Targets. <i>Digestive Diseases</i> , 2015, 33, 586-589.	0.8	2
24	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464.	1.8	106
25	Assessment of Nuclear Nanomorphology Marker to Improve the Detection of Malignancy From Bile Duct Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2014, 141, 884-891.	0.4	7
26	Molecular Pathogenesis of Cholangiocarcinoma. <i>Digestive Diseases</i> , 2014, 32, 564-569.	0.8	35
27	Current Diagnostic and Management Options in Perihilar Cholangiocarcinoma. <i>Digestion</i> , 2014, 89, 216-224.	1.2	35
28	Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis. <i>Journal of Biological Chemistry</i> , 2014, 289, 22835-22849.	1.6	47
29	Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. <i>Gastroenterology</i> , 2013, 145, 1215-1229.	0.6	978
30	Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect". <i>Journal of Cancer</i> , 2013, 4, 626-634.	1.2	4
31	Response to Michael. <i>American Journal of Gastroenterology</i> , 2012, 107, 950-951.	0.2	1
32	Nuclear Refractive Index Properties of Non-Dysplastic Metaplastic Cells to Detect the Presence of Esophageal High-Grade Dysplasia and Adenocarcinoma From Barrett's Esophagus. <i>Gastroenterology</i> , 2011, 140, S-217.	0.6	3
33	Supplementation With Oral vs. Intravenous Iron for Anemia With IBD or Gastrointestinal Bleeding: Is Oral Iron Getting a Bad Rap?. <i>American Journal of Gastroenterology</i> , 2011, 106, 1872-1879.	0.2	38
34	Combinatorial Chemoprevention Reveals a Novel Smoothed-Independent Role of GLI1 in Esophageal Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 6787-6796.	0.4	42